India, Nov. 18 -- Cipla Limited announced that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc., has received a 'No Action Indicated' (NAI) classification from the US Food and Drug Administration (USFDA) for its manufacturing facility in Hauppauge, Long Island, New York.

The USFDA conducted the facility inspection from October 19 to October 22, 2026. The NAI classification indicates that no objectionable conditions or regulatory violations were identified during the inspection.

Published by HT Digital Content Services with permission from Dion Global Solutions Limited....